FIELD: biotechnology.
SUBSTANCE: disclosed are fully human antibodies which bind to receptor tyrosine kinase RET, nucleic acids coding said antibodies, expression vectors containing said nucleic acids. Also disclosed is the use of antibodies to RET for treating diseases, disorders or pathological conditions associated with expression, activation or transmission of a signal of the receptor tyrosine kinase RET gene or its rearranged form. Also disclosed is the use of the antibodies according to the invention for treating cancer and pain associated with cancer, or for relieving pain associated with other pathological conditions associated at least in part with expression, activation or transmission of RET signals.
EFFECT: disclosed antibodies specifically binding RET can be useful for slowing growth or proliferation of tumour cells, as well as for relieving pain associated with cancer and other pathological conditions.
32 cl, 1 dwg, 6 tbl, 6 ex
| Title | Year | Author | Number |
|---|---|---|---|
| HUMAN ANTIBODIES TO Fel d1 AND METHODS OF USE THEREOF | 2013 |
|
RU2658491C2 |
| HUMANIZED ANTI-SIRPα ANTIBODIES | 2019 |
|
RU2812199C2 |
| USE OF BISPECIFIC ANTIGEN-BINDING MOLECULES THAT BIND PSMA AND CD3, IN COMBINATION WITH COSTIMULATION 4-1BB | 2020 |
|
RU2822092C2 |
| ANTI-ANGPTL3 ANTIBODIES AND THEIR APPLICATION | 2012 |
|
RU2620064C2 |
| USE OF BISPECIFIC ANTIGEN-BINDING MOLECULES THAT BIND MUC16 AND CD3, IN COMBINATION WITH COSTIMULATION 4-1BB | 2020 |
|
RU2822091C2 |
| ANTI-SIRPα ANTIBODIES | 2018 |
|
RU2771174C2 |
| ANTIBODIES AGAINST HUMAN GDF8 | 2011 |
|
RU2567805C2 |
| GDF8 HUMAN ANTIBODIES | 2011 |
|
RU2710156C2 |
| METHODS FOR TREATING EOSINOPHILIC ESOPHAGITIS BY ADMINISTERING AN IL-4R INHIBITOR | 2014 |
|
RU2679141C2 |
| SCLEROSTIN ANTIBODY, ITS ANTIGEN-BINDING FRAGMENT AND MEDICAL APPLICATION | 2016 |
|
RU2716101C2 |
